BioNTech — developer of the individualized mRNA neoantigen vaccine autogene cevumeran (BNT122), notably in pancreatic cancer.
Log in here to read the desired article. BioNTech and Genentech have terminated a Phase 2 trial of their personalized mRNA cancer vaccine autogene cevumeran in colorectal cancer after more deaths occurred in the vaccine arm than among patients under observation. The setback comes…
MIAMI, Aug. 24, 2026 /PRNewswire/ -- BreakBio, the third player in personalized drugs after Moderna and BioNTech and the top private company in the personalized drugs space with advanced cutting-edge technology, is entering the clinic next quarter. BreakBio aims to be not first-i…
Follow-up data from the phase 2b KEYNOTE-942 trial shows that BioNTech’s mRNA-4157 combined with pembrolizumab reduced the risk of recurrence or death by 49% in high-risk stage III/IV melanoma patients compared to pembrolizumab alone. The combination also cut the risk of distant metastases or death by 62% at a median follow-up of three years. These results support the clinical benefit of personalized neoantigen mRNA vaccines in adjuvant settings.
A recent review in Signal Transduction and Targeted Therapy highlights the clinical translation of personalized mRNA vaccines, citing Moderna’s mRNA-4157 and BioNTech’s autogene cevumeran for reducing recurrence risk. The article contrasts these advances with the historical limitations of therapeutic cancer vaccines, noting Sipuleucel-T as the sole FDA-approved example to date. It outlines various vaccine platforms and the immunological challenges remaining in the field.